Belharra Therapeutics

Belharra Therapeutics is a private drug discovery company that has pioneered a novel photoaffinity-based chemoproteomics platform to disrupt the drug discovery paradigm. Guided by a diverse team of biotech pioneers, Belharra's proprietary discovery engine has the unique ability to identify novel non-covalent small-molecule starting points for the development of transformative drugs to address previously difficult-to-treat diseases and conditions. The company’s next-generation chemoproteomics platform enables Belharra scientists to identify small-molecule candidates for any binding site, any protein, any conformational state, and any cell type.